Regulation of medicines, biotechnology devices and healthcare products | Zendy

E. R. Sykes | Zendy; David Pye | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Regulation of medicines, biotechnology devices and healthcare products

Author(s) -

E. R. Sykes,

David Pye

Publication year - 2018

Publication title -

the biochemist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.126

H-Index - 7

eISSN - 1740-1194

pISSN - 0954-982X

DOI - 10.1042/bio04006044

Subject(s) - brexit , european union , agency (philosophy) , regulatory agency , health care , business , international trade , political science , public administration , law , sociology , social science

On 20 November 2017 the European Medicines Agency (EMA) announced their intention to relocate from London to Amsterdam due to the UK's decision to leave the European Union. It is nearly 12-months to the day since this announcement, and, other than the movement of a major regulatory headquarters, the UK is no closer to knowing what impact Brexit is likely to have on the regulation of medicines and healthcare products in the UK.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research